Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Nov 21, 2006

Proteologics Reports Progress in Drug Discovery Collaboration with Teva Pharmaceutical

  • Proteologics achieved a milestone in its collaboration with Teva Pharmaceuticals to research, develop, and commercialize novel anti-cancer therapeutics. Proteologics and Teva partnered in two independent, yet complementary projects, focusing on specific components of the ubiquitin system.

    Successful identification and validation of a novel target triggered entrance into the second phase of the collaboration moving ahead into drug discovery.

    Under the agreement, Proteologics is responsible for research and early drug discovery activities while Teva retains the option to continue development through preclinical and clinical phases, as well as commercialization of products. Proteologics is entitled to payments pending on the achievement of clinical development milestones, as well as royalties from sales.



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »